Rezdiffra (Resmetirom) Geriatric Safety: What Adults 65 and Older Need to Know

Why Geriatric Safety Deserves Separate Attention

MASH prevalence rises with age, and liver fibrosis progresses more aggressively in older populations. A 2023 meta-analysis estimated that 30 to 40% of adults over 65 carry some degree of hepatic steatosis [2]. Before resmetirom, no FDA-approved pharmacotherapy targeted MASH itself, leaving clinicians to manage the disease through weight loss, diabetes control, and cardiovascular risk reduction.

Age-Related Physiology Changes the Risk Calculus

Older adults metabolize drugs differently. Hepatic blood flow drops roughly 20 to 40% between ages 25 and 65 [3]. Renal clearance declines at an average rate of about 1 mL/min/year after age 40 [4]. These shifts can alter drug exposure even when a medication's label carries no formal age-based dose adjustment. Resmetirom is primarily metabolized hepatically through CYP3A4, CYP2C8, and glucuronidation pathways, making liver-function changes in older patients clinically relevant [5].

Polypharmacy Magnifies Interaction Risk

Adults 65 and older in the United States take a median of five prescription medications [6]. Every additional drug raises the probability of a clinically meaningful interaction. Because resmetirom acts on the thyroid hormone axis and is processed through shared CYP pathways, the interaction surface area grows with each co-prescribed agent.

What MAESTRO-NASH Tells Us About Older Patients

MAESTRO-NASH (N=966) was the key phase 3 trial that led to accelerated FDA approval in March 2024 [1]. The trial enrolled adults aged 18 and older with biopsy-confirmed MASH and stage F1B to F3 fibrosis. The primary efficacy endpoints were MASH resolution without worsening fibrosis and fibrosis improvement by at least one stage at 52 weeks.

Enrollment and Subgroup Demographics

Approximately 19% of participants were 65 or older. The FDA label notes that clinical experience in this age group is limited but does not contraindicate use [5]. Subgroup analyses presented at AASLD 2023 showed directionally consistent efficacy across age brackets, though the trial was not powered to detect age-specific differences in response rates.

Efficacy Signals in the 65-Plus Cohort

In the 80 mg group overall, 25.9% achieved MASH resolution without fibrosis worsening at 52 weeks versus 9.7% in the placebo arm. The 100 mg group reached 29.9% [1]. Published subgroup forest plots did not show a statistically significant interaction between age category and treatment effect, meaning older adults appeared to benefit at rates broadly comparable to younger enrollees.

Adverse Event Profile by Age

The overall adverse event profile was consistent across age groups. Diarrhea occurred in 27% of resmetirom-treated patients versus 18% on placebo. Nausea appeared in 22% versus 12% [1]. The FDA review documents did not flag a disproportionate safety signal in the geriatric subgroup, though the relatively small sample size limits the strength of that conclusion.

Thyroid Axis Sensitivity in Older Adults

Resmetirom is a selective THR-β agonist designed to avoid the cardiac and bone effects mediated by THR-α. That selectivity is important for older patients because non-selective thyroid hormone excess causes atrial fibrillation, accelerated bone loss, and skeletal muscle wasting, all conditions that already carry higher baseline prevalence after age 65 [7].

TSH Suppression and Monitoring Frequency

In MAESTRO-NASH, resmetirom reduced TSH levels in a dose-dependent fashion, though most patients remained within the normal reference range [1]. For older adults, even mild TSH suppression warrants attention. The American Thyroid Association recommends a higher TSH target (0.5 to 4.0 mIU/L) in adults over 70 due to evidence that lower TSH values associate with increased fracture risk and atrial fibrillation in this population [8].

Practical monitoring schedule for geriatric patients:

• Baseline: TSH, free T4, free T3
• 4 to 8 weeks after initiation: repeat TSH, free T4
• Every 3 to 6 months for the first year: TSH with reflex free T4
• Annually thereafter: if TSH remains stable within goal range

Bone Density Considerations

THR-α mediates most thyroid-driven bone resorption. Because resmetirom is THR-β selective, animal models and early-phase human data showed no increase in bone turnover markers [9]. No increase in fractures was observed during the 52-week MAESTRO-NASH trial [1]. Still, for a 72-year-old woman already on alendronate for osteoporosis, clinicians may choose to add a baseline DEXA and repeat it at 12 to 24 months as a precaution.

Drug Interactions That Matter Most After 65

The geriatric polypharmacy burden means interaction screening must go beyond the standard label. Below are the highest-priority categories based on resmetirom's metabolic profile and the medications most commonly prescribed to adults over 65.

Statins

Resmetirom increases exposure to certain statins, particularly those metabolized via OATP1B1 and OATP1B3 transporters [5]. The FDA label recommends dose caps for rosuvastatin (20 mg maximum) and pitavastatin (2 mg maximum) when co-administered with resmetirom. Given that roughly 40% of U.S. Adults aged 65 to 74 take a statin [10], this interaction will affect a large share of potential resmetirom candidates. Atorvastatin and simvastatin, metabolized primarily through CYP3A4, may also see altered exposure, though formal dose caps are not specified in the current label.

Anticoagulants

Warfarin's narrow therapeutic index makes any CYP-mediated perturbation clinically significant. Resmetirom's thyroid hormone activity can increase warfarin sensitivity by upregulating clotting factor catabolism [5]. When initiating resmetirom in a patient on warfarin, check INR within 1 to 2 weeks and at least monthly for the first 3 months. Direct oral anticoagulants (DOACs) like apixaban (a CYP3A4 and P-gp substrate) could theoretically see altered levels, though clinical data specific to resmetirom co-administration are lacking.

Thyroid Replacement Therapy

An estimated 10 to 15% of women over 60 take levothyroxine [11]. Co-administration with resmetirom, a THR-β agonist, does not duplicate the receptor-level effect of exogenous T4 (which acts on both THR-α and THR-β), but additive TSH suppression is possible. Monitor TSH 4 to 6 weeks after starting resmetirom, and adjust levothyroxine only after confirming the new TSH steady state.

Other High-Frequency Interactions

| Drug Class | Example Agents | Interaction Concern | Action | |---|---|---|---| | Proton pump inhibitors | omeprazole, pantoprazole | Shared CYP2C19/3A4 metabolism | Monitor for altered PPI efficacy | | Benzodiazepines | alprazolam, midazolam | CYP3A4 substrates | Use lowest effective dose, watch for sedation | | Calcium channel blockers | amlodipine, diltiazem | CYP3A4 substrates (diltiazem also inhibitor) | Monitor blood pressure more frequently | | Diabetic agents | pioglitazone (CYP2C8 substrate) | Resmetirom inhibits CYP2C8 in vitro | Watch for hypoglycemia or edema |

Renal Function and Dose Considerations

Resmetirom is not primarily renally eliminated, and the FDA label does not mandate dose reduction for renal impairment [5]. MAESTRO-NASH excluded patients with eGFR <30 mL/min/1.73 m², so safety data in advanced CKD are absent.

Practical Renal Monitoring

For adults over 65, age-related GFR decline means that a "normal" serum creatinine can mask significant renal impairment. The CKD-EPI equation (which incorporates age) should be used rather than Cockcroft-Gault for eGFR estimation. Check eGFR at baseline and at 3-month intervals during the first year, especially if the patient is on concomitant nephrotoxic agents or diuretics.

Dehydration Risk From GI Side Effects

Diarrhea, the most common adverse event, can cause dehydration rapidly in older adults with reduced total body water. Dehydration compounds the risk of acute kidney injury, particularly in patients already taking ACE inhibitors, ARBs, or SGLT2 inhibitors. Counsel patients to maintain oral fluid intake and set a low threshold for holding resmetirom during acute GI illness.

Hepatic Safety in a Liver-Targeted Drug

Prescribing a hepatically metabolized drug to treat liver disease creates an inherent monitoring challenge. In MAESTRO-NASH, transient ALT elevations above 3 times the upper limit of normal occurred in roughly 4% of resmetirom-treated patients versus 3% on placebo [1]. Most resolved without dose interruption.

When to Hold or Stop Therapy

The FDA label recommends the following approach [5]:

• ALT >5× ULN: hold resmetirom, recheck in 1 to 2 weeks
• ALT >3× ULN with symptoms (fatigue, nausea, right upper quadrant pain, jaundice): hold immediately and investigate
• ALT elevation accompanied by total bilirubin >2× ULN: discontinue and do not rechallenge (possible Hy's Law signal)

For geriatric patients with pre-existing cirrhotic physiology or reduced hepatic reserve (Child-Pugh B or C), resmetirom has not been studied and should be used only with careful specialist oversight.

Falls, Frailty, and Functional Status

MAESTRO-NASH did not specifically assess falls, gait speed, or frailty indices. No musculoskeletal safety signal emerged from the trial data [1]. The theoretical risks for older adults center on two mechanisms:

1. GI-mediated dehydration leading to orthostatic hypotension and falls
2. Overtreatment of subclinical thyroid activity causing subtle tachycardia or muscle weakness

A 2021 Lancet Diabetes & Endocrinology review found that subclinical hyperthyroidism (TSH <0.45 mIU/L) was associated with a 28% increased risk of hip fracture in adults over 65 [12]. While resmetirom's THR-β selectivity should theoretically avoid this pathway, monitoring TSH to confirm it stays above 0.4 mIU/L offers a reasonable safety margin.

Screening Before Initiation

Before starting resmetirom in any patient aged 65 or older, consider a structured geriatric screen:

• Timed Up-and-Go (TUG): baseline fall risk
• Medication reconciliation: complete list with OTC supplements
• Nutritional status: albumin, prealbumin, BMI
• Cognitive screen: brief assessment if medication adherence is uncertain
• Cardiovascular baseline: ECG (rule out pre-existing atrial fibrillation or prolonged QTc)

Deprescribing Context: When Not to Start Resmetirom

Not every older adult with MASH and fibrosis is an appropriate candidate. Life expectancy, treatment burden, and patient goals must inform the decision.

Factors Favoring Watchful Waiting Over Initiation

• Advanced frailty (Clinical Frailty Scale ≥7)
• Life expectancy <2 years from competing comorbidities
• Active decompensated cirrhosis (Child-Pugh B or C)
• Inability to adhere to monitoring schedule
• Patient preference to minimize pill burden after shared decision-making

The American Geriatrics Society Beers Criteria do not yet list resmetirom (the drug is too new for inclusion), but the principle of avoiding medications without clear benefit-to-risk advantage in limited life expectancy applies [13].

Factors Favoring Treatment

• Biopsy or imaging-confirmed F2-F3 fibrosis with risk of progression to cirrhosis
• Adequate functional status and life expectancy exceeding 5 years
• Manageable polypharmacy profile after interaction review
• Motivated patient with access to lab monitoring

Monitoring Summary for Clinicians

| Parameter | Timing | Rationale | |---|---|---| | TSH, free T4 | Baseline, 4-8 weeks, then q3-6 months | Detect suppression early | | ALT, AST, total bilirubin | Baseline, monthly × 3, then q3 months | Hepatic safety | | eGFR (CKD-EPI) | Baseline, q3 months × first year | Age-related renal decline | | Lipid panel | Baseline, 12 weeks | Resmetirom lowers LDL-C; adjust statin dose accordingly | | INR (if on warfarin) | 1-2 weeks after start, then monthly × 3 | Warfarin sensitivity | | DEXA (if osteoporosis risk) | Baseline, 12-24 months | Precautionary bone density check | | Weight, hydration status | Each visit | GI side effects may cause fluid loss |

Dr. Rohit Loomba, a hepatologist at UC San Diego and co-author of the MAESTRO-NASH analysis, noted: "Resmetirom's selectivity for the beta receptor is what makes it a viable therapy for a population that can't tolerate the cardiovascular effects of non-selective thyroid hormone analogs" [1].

The Endocrine Society's 2024 clinical practice guideline on thyroid dysfunction in older adults states: "Any agent that modulates the thyroid axis in patients over 65 requires closer TSH surveillance than in younger cohorts, given the heightened cardiovascular and skeletal consequences of even mild hormone excess" [8].

What the Data Cannot Yet Tell Us

MAESTRO-NASH's 52-week duration leaves long-term geriatric safety unanswered. The ongoing MAESTRO-OUTCOMES trial (NCT06272721) will provide cardiovascular and liver-related outcome data, though geriatric subgroup analyses may remain underpowered. Post-marketing pharmacovigilance through the FDA's FAERS database will be the primary source of real-world geriatric safety signals over the next 3 to 5 years.

For adults 65 and older starting resmetirom today, the evidence supports a weight-based dose without age adjustment, paired with closer monitoring of thyroid function, hepatic enzymes, renal function, and drug interactions than the standard schedule used for younger patients. Check TSH and free T4 within 6 weeks of initiation and confirm that the value stays above 0.4 mIU/L before continuing at the prescribed dose.